Last edition
News about "Ropidoxuridine"
Shuttle Pharma Finalizes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine
Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.
Ropidoxuridine | 29/10/2024 | By Aishwarya
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
Ropidoxuridine | 04/08/2023 | By Sudeep Soparkar | 339
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy